GMED vs RDNT
Globus Medical vs RadNet, Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
RDNT
RadNet, Inc.
52
Watch
| Metric | GMED | RDNT |
|---|
| AI Score |
71
|
52
|
| Price |
$85.12
|
$76.28
|
| P/E Ratio |
21.45×
|
-286.45×
|
| ROE |
11.8%
|
-1.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
9.7%
|
| Debt / Equity |
0.02×
|
1.99×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.9
|
78.1
|
| Beta |
0.954
|
1.384
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus RDNT.
GMED leads by 19 points.
GMED scores 71/100 (Buy) versus RDNT at 52/100 (Watch).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
RDNT Committee View
33% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — price-to-book of 5.1x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 5.1x prices in significant intangible value — Value
- ROE of only -1.4% -- cheap may mean cheap for a reason — Value
- RSI at 78 is in overbought territory — Technical